Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.

Stephanie A VuijkMaria M E JongsmaBritt M HoevenMaarten A CozijnsenMerel van PietersonTim G J de MeijObbe F NorbruisMichael GroenewegVictorien M WoltersHerbert van WeringThalia HummelJanneke StapelbroekCathelijne van der FeenPatrick Ferry van RheenenMichiel P van WijkSarah TeklenburgDimitris RizopoulosMarten J PoleyJohanna C Escher Lissy de Ridder

Published in: Alimentary pharmacology & therapeutics (2024)

NCT02517684.

Keyphrases

clinical trial
open label
double blind
study protocol
emergency department
intensive care unit
phase ii
randomized controlled trial
phase iii
placebo controlled
combination therapy